ArticleIJU case reports2026
Invasive Bladder Cancer With Peritoneal Invasion and Rectal Involvement Causing Rectal, Bilateral Ureteral, and Common Bile Duct Obstruction Without a Retroperitoneal Mass: A Case Report.
Article in IJU case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Bladder cancer (BC) is rarely associated with common bile duct (CBD) obstruction. We report a case of BC with peritoneal invasion and rectal involvement complicated by bilateral ureteral and biliary obstruction. Case Presentation: A 77-year-old man presented with abdominal pain. Imaging revealed a bladder tumor with suspected muscle invasion, rectal obstruction, and bilateral hydronephrosis. Urothelial carcinoma was confirmed after transurethral resection of the bladder. Following the operation, the patient developed cholangitis with CBD obstruction, and in the absence of direct invasion or mass-like lesions suggestive of malignant retroperitoneal fibrosis, retroperitoneal extension was considered a possible mechanism. Safety concerns regarding enfortumab vedotin in the setting of biliary obstruction led us to administer pembrolizumab monotherapy. Conclusion: BC may contribute to biliary obstruction through retroperitoneal processes, underscoring the need for careful diagnostic and therapeutic assessment. Furthermore, biliary drainage enabled the initiation of systemic therapy, highlighting the importance of appropriate supportive intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.